Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04230499 · ClinicalTrials.gov registry record · Phase 2
Trial of ERapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance
A Phase 2 study of Familial Adenomatous Polyposis, sponsored by Rapamycin Holdings.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 4
- Study locations
NCT04230499: Active Phase 2 study of Familial Adenomatous Polyposis, sponsored by Rapamycin Holdings.
NCT04230499 is a Phase 2 study of Familial Adenomatous Polyposis that is active but no longer recruiting, run by Rapamycin Holdings. The registered enrollment target is 30 participants, below the 246-participant average among 10 other Familial Adenomatous Polyposis trials with a reported enrollment target (88% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04230499, a Phase 2 study of Familial Adenomatous Polyposis, is active but no longer recruiting, sponsored by Rapamycin Holdings.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 4
- Study locations
Study Summary
Patients with Familial Adenomatous Polyposis (FAP) who are undergoing endoscopic surveillance will be given Encapsulated Rapamycin (eRapa) at one of three escalating doses/schedules for 12 months with the aim of reducing polyp burden.
Conditions Studied
Interventions
- DRUG Encapsulated Rapamycin (eRapa)
Study Locations (4)
Ohio
- Cleveland Clinic - Cleveland
- Ohio State University - Columbus
Michigan
- Michigan Medicine - Ann Arbor
Texas
- UT Health - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-01-18 |
| Est. Completion | 2025-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04230499
The ClinicalTrials.gov registry entry for NCT04230499 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 10 other Familial Adenomatous Polyposis trials with a reported enrollment target (88% lower). The listed sponsor is Rapamycin Holdings, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Familial Adenomatous Polyposis appearing as the primary indexed condition, and to 1 intervention - of which Encapsulated Rapamycin (eRapa) is the first listed.
NCT04230499 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Ohio, Michigan, Texas.
Frequently Asked Questions
What is clinical trial NCT04230499 about?
NCT04230499 is a clinical study titled "Trial of ERapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance". Patients with Familial Adenomatous Polyposis (FAP) who are undergoing endoscopic surveillance will be given Encapsulated Rapamycin (eRapa) at one of three escalating doses/schedules for 12 months with the aim of reducing polyp burden.
What is the current status of trial NCT04230499?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2021-01-18. Estimated completion is 2025-03.
What conditions does trial NCT04230499 study?
This clinical trial studies the following conditions: Familial Adenomatous Polyposis.
What interventions are being tested in trial NCT04230499?
The interventions under investigation include: Encapsulated Rapamycin (eRapa) (DRUG).
Who is sponsoring clinical trial NCT04230499?
This trial is sponsored by Rapamycin Holdings, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04230499 being conducted?
This trial has 4 study locations across Michigan, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Familial Adenomatous Polyposis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Curcumin in Treating Patients With Familial Adenomatous Polyposis
COMPLETED · Phase 2
-
A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis
RECRUITING
-
A Personalized Surveillance and Intervention Protocol for Patients With Familial Adenomatous Polyposis That Have Undergone (Procto)Colectomy
RECRUITING
-
Investigation of β-hydroxybutyrate Supplementation as Chemoprevention in Familial Adenomatous Polyposis
RECRUITING · NA
-
Testing for Safety and Colorectal Cancer Preventive Effects of ONC201
RECRUITING · Phase 1
-
Trial of Exercise Therapy in Familial Adenomatous Polyp (FAP)
RECRUITING · NA
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.